Doctors with M.E. Board, Fellows & Associates are co-signatories to a public letter written by Dr. David Tuller of the Center of Global Public Health at the University of California, Berkeley. The letter writes to urge NICE to publish the new ME/CFS guideline. It is signed by scientists, clinicians, academics and other experts from the…Continue readingGlobal scientific communities and clinicians urge NICE to publish ME/CFS guideline now
Category: Compliance
A call for change in the face of long-standing regulatory failure The following public communication from our Governance Board regards the opportunity for a new “Medical Regulatory Agency”, ready for the post-brexit and the machine learning digital eras. The letter also contains background pertaining to long-standing regulatory failure, unlawful medical norms, contra-scientific medical belief systems and…Continue readingPublic Letter to DHSC, MHRA, HoC, NICE: Call for a ‘Medical Regulatory Agency’
We are very disappointed to hear of the ‘pause’ in publication of the NICE ME/CFS Guideline, already delayed in April. Following the hard work of the Guideline Development Group, we received news of the further delay of guideline publication with both dismay and profound concern for practitioners, their organisations and patients. Continued delay or deviation…Continue readingRapid Response and Expert Comment: NICE Guideline Delay and Accommodation of Unlawfulness
Your questions regarding the new NICE Guideline announcement this week have been broken down and addressed by Doctors with M.E. Honorary Fellow, Professor Brian Hughes: 1. What’s going on? 2. How is the new guideline different to the old one? 3. Why is the new guideline being welcomed? 4. Why was the old guideline problematic?…Continue readingHonorary Fellow on the new NICE Guideline for ME/CFS: Ten Questions Answered
Is it just me, or is the BMJ’s take on those NICE guideline committee resignations maybe a little biased? The BMJ are reporting that four members of NICE’s guideline committee on ME/CFS have stood down. One is the medical advisor of the ME Association, who stated yesterday that he found it too difficult to combine…Continue readingHonorary Fellow comments on the BMJ and NICE Guideline Committee Resignations
It is common that patients with ME/CFS must repeatedly pursue enforcement action of their pre-existing rights under statutes, policy and common law. It also known that successful enforcement of pre-existing rights can be followed by retributory abuse of power and authority. It is known that flagrantly retributory liability generation can include punishing qualified professionals who…Continue readingObligation to not abuse power and authority
Informed by the scientific, statutory and policy contexts outlined above, the following simple tests of clinical judgement lawfulness further outline lawful policy implementation requirements, mitigating the elevated probability of normalised unlawful clinical judgement in this context. Contrary conclusions constitute unlawful discriminatory implementation of policy, an arbitrary evasion of clear wording, thus discriminating on the very…Continue readingTests of clinical judgement lawfulness
Care should be taken to reassess existing expertise sources in the field of post-viral disease and to distinguish between 1) the marketability or familiarity of expertise versus 2) disproportionate risk of divergence from legally sustainable standards. It is rare for institutionalised medical norms to exclude scientific consensus to the degree witnessed in this field. This…Continue readingExpertise procurement risk and reputational risk – medical and legal
Although the jurisdictional focus is the United Kingdom, direct equivalence can be found in other jurisdictions and markets. The policy, contractual and legal requirements on medical practice and indemnification provision follow a similar structure in most locales: neither official edict, professional body, private contract, the habitual nature of unlawful care nor eminently misinformed obfuscation can…Continue readingJurisdictions and markets (UK and international)
The absolute clarity of the legal status of ME/CFS is of immediate risk management importance, due its statutory, policy and third-party contractual implications frequently being ignored. These stem from habitually unlawful clinical judgement and arbitrarily discriminative administrative treatment that fail to account for the clarity of classification and associated lawful obligations. The absolute clarity of…Continue readingObligation to not negate ME/CFS legal status